MOTS-c vs SS-31: Complete 2026 Comparison
Side-by-side comparison of MOTS-c and SS-31: mechanism, common use cases, dosing protocols from named experts, vendor availability, and expert opinion. Both are framed as research compounds.
TL;DR Table
| Factor | MOTS-c | SS-31 |
|---|---|---|
| Class | PEPTIDE | PEPTIDE |
| Aliases | [] | ["Elamipretide (likely)"] |
| Mechanism | n/a | n/a |
| What it's researched for | Mitochondrial-derived peptide used as part of a broader mitochondrial support stack. | Stabilizes the inner mitochondrial membrane, prevents oxidative stress from leaky mitochondria, and may protect kidneys against steroid-induced damage. |
| Dosing mentions tracked | 100 | 62 |
| Vendor recs tracked | 9 | 17 |
| PubMed papers | 8 | 8 |
Mechanism Comparison
What Each is Researched For
MOTS-c research areas
Mitochondrial-derived peptide used as part of a broader mitochondrial support stack.
SS-31 research areas
Stabilizes the inner mitochondrial membrane, prevents oxidative stress from leaky mitochondria, and may protect kidneys against steroid-induced damage.
Dosing Mention Comparison
MOTS-c dosing
- speaker_1: According to the narrator, it's most effective in a fasted state when insulin is low and glucose is less available, specifically paired... (00:00:33)
- speaker_1: Speaker 1 reported using 10 mg once weekly in the morning for about 8 to 12 weeks; not a daily protocol. (00:00:38)
- speaker_1: Speaker_1 reported using an optional loading phase: running MOTS-c two to three times per week during the first 2 weeks to reach... (00:00:46)
- Narrator: Anecdotal report: 0.5 to 1 mg subcutaneously resulted in slight post-injection irritation, mild redness ~24 hours, no pain. (00:00:53)
- narrator: 0.5-1 mg subcutaneously (anecdotal report): slight post-injection irritation, no pain, mild redness lasting ~24 hours; reported wave of... (00:00:53)
SS-31 dosing
- VigorousSteve: 2 mg to 40 mg daily for mitochondrial/oxidative stress protection (00:02:06)
- Vigorous Steve: Vigorous Steve reported a dosing range of 2 mg to 40 mg daily being discussed in the context of oxidative stress and mitochondrial... (00:02:06)
- Vigorous Steve: Vigorous Steve reported anecdotal use of SS-31 at 2 mg to 40 mg daily for oxidative stress and mitochondrial protection support. (00:02:06)
- Vigorous Steve: Maintenance: 1-2 mg/day; Healing: 5-10 mg/day; Full medical dose: 40 mg/day (00:07:38)
- Steve: Steve reported (anecdotal, source iQ9JgQV-VRo) a maintenance range of 1-2 mg/day, a healing range of 5-10 mg/day, and a full... (00:07:40)
Side Effect Notes
Anecdotal reports for both compounds vary by route, dose, and individual. Neither should be treated as an approved medication. Consult a qualified clinician.
When To Choose Which
Comparison depends on research question, available source quality, and individual risk tolerance. See the full profiles for MOTS-c and SS-31 for context-specific details.
Can You Stack Them?
Stacking decisions should be evaluated by qualified professionals with attention to dose attribution, source quality, and outcome tracking. This page is a research aggregator and does not recommend stacking protocols.
FAQ
Which has more research?
MOTS-c has 8 PubMed citations indexed; SS-31 has 8.
Which has more vendor coverage?
MOTS-c: 9 tracked vendor recommendations. SS-31: 17.
Are they approved drugs?
Both are framed on this site as research compounds. Verify current FDA status and state-specific rules before any decision.